文献速递泌尿男性生殖肿瘤

2003年Leibovich评分在SORCE试验随机分组患者中的外部验证:一项国际III期肾细胞癌辅助索拉非尼试验

External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer.
PubMed 文献 · J Clin Oncol · 2022-02-25

该研究利用SORCE试验(国际随机III期辅助索拉非尼试验)的当代数据,对2003年Leibovich评分进行外部验证,评估其对透明细胞肾细胞癌患者无转移生存的区分度和校准度。结果显示该评分能区分中危和高危患者(HR 2.74,95%CI 2.29-3.28),但校准度欠佳(HR 0.61,95%CI 0.53-0.70),在非透明细胞、乳头状和嫌色细胞癌亚组中也有一定区分度。结论支持该评分用于辅助临床试验的风险分层。

要点

  • 2003年Leibovich评分在SORCE当代数据中能区分中危和高危透明细胞肾细胞癌患者(HR 2.74)。
  • 该评分校准度欠佳(HR 0.61,95%CI 0.53-0.70),提示随时间推移无转移生存已改善。
  • 在非透明细胞、乳头状和嫌色细胞癌亚组中,评分也显示出区分度(c-index 0.64、0.63、0.65)。

核心结论

  • 2003年Leibovich评分在当代数据中能区分中危和高危透明细胞及非透明细胞肾细胞癌组,支持其用于辅助临床试验的风险分层。
  • 随着时间的推移,局部晚期肾细胞癌患者的无转移生存已改善。
  • 应使用辅助肾细胞癌试验的当代数据来改进肾细胞癌患者的预后预测。

研究设计与样本

  • 研究为对2003年Leibovich评分的外部验证,使用SORCE试验(国际随机III期辅助索拉非尼试验)的当代数据。
  • 主要分析纳入透明细胞肾细胞癌患者,采用Cox比例风险回归、Kaplan-Meier曲线和Harrell's c指数评估无转移生存的区分度和校准度。
  • 次要分析涉及SORCE中三个重要亚组:任何非透明细胞亚型、乳头状和嫌色细胞癌。
  • Leibovich队列包含982例患者,记录407例复发;主要SORCE队列包含1445例患者,记录520例复发。

主要发现

  • 在SORCE透明细胞癌队列中,中危和高危组之间显示出清晰的区分度,风险比(HR)为2.74(95%CI,2.29至3.28),c指数为0.63(95%CI,0.61至0.65)。
  • HR为0.61(95%CI,0.53至0.70)证实两个队列的校准度欠佳。
  • 在次要分析中观察到区分度:非透明细胞肾细胞癌的c指数为0.64(95%CI,0.59至0.69),乳头状肾细胞癌为0.63(95%CI,0.56至0.69),嫌色细胞癌为0.65(95%CI,0.55至0.76)。

临床怎么用

  • 作者认为,2003年Leibovich评分可用于辅助临床试验的风险分层。
  • 作者建议,应使用辅助肾细胞癌试验的当代数据来改进肾细胞癌患者的预后预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The 2003 Leibovich score guides prognostication and selection to adjuvant clinical trials for patients with locally advanced renal cell carcinoma (RCC) after nephrectomy. We provide a robust external validation of the 2003 Leibovich score using contemporary data from SORCE, an international, randomized trial of sorafenib after excision of primary RCC. METHODS: Data used to derive the 2003 Leibovich score were compared with contemporary data from SORCE. Discrimination and calibration of the metastasis-free survival outcome were assessed in data from patients with clear-cell RCC, using Cox proportional hazards regression, Kaplan-Meier curves, and calculation of Harrell's c indexes. Secondary analyses involved three important SORCE groups: patients with any non-clear-cell subtype, papillary, and chromophobe carcinomas. RESULTS: Four hundred seven recurrences occurred in 982 patients in the Leibovich cohort and 520 recurrences were recorded in 1,445 patients in the primary SORCE cohort. Clear discrimination between intermediate-risk and high-risk SORCE cohorts was shown; hazard ratio 2.74 (95% CI, 2.29 to 3.28), c-index 0.63 (95% CI, 0.61 to 0.65). A hazard ratio of 0.61 (95% CI, 0.53 to 0.70) confirmed poor calibration of the two cohorts. Discrimination was observed in secondary populations, with c-indexes of 0.64 (95% CI, 0.59 to 0.69) for non-clear-cell RCC, 0.63 (95% CI, 0.56 to 0.69) for papillary RCC, and 0.65 (95% CI, 0.55 to 0.76) for chromophobe RCC. CONCLUSION: The 2003 Leibovich score discriminates between intermediate-risk and high-risk clear-cell and non-clear-cell RCC groups in contemporary data, supporting its use for risk stratification in adjuvant clinical trials. Over time, metastasis-free survival for patients with locally advanced RCC has improved. Contemporary data from adjuvant RCC trials should be used to improve prognostication for patients with RCC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Oza B, Eisen T, Frangou E, et al. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol. 2022. PMID: 35213214. doi:10.1200/JCO.21.01090

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。